working with Lab central. He said, “External innovation is critically important in helping us achieve our VISION of turning innovative science into VALUE for patients. Combining our R&D capabilities and expertise with LabCentral’s established network and launchpad in the Boston area, we look to bring hope to patients worldwide by partnering with emerging biotechnology companies and transforming their ideas into reality.”
LabCentral Co-founder and President, Johannes Fruehauf, expressed optimism about the latest partnership. He said, “We are extremely pleased to be working with Astellas to foster life-science innovation in the Boston area. Our labs offer a fertile environment in which biotechnology visionaries can thrive by providing them with the space and resources they need to test out, challenge, and nurture early ideas. We are excited that Astellas has chosen to create the Future Innovator Prize program to supplement their external innovation initiatives.”
